NCT00224146View on ClinicalTrials.gov

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

PHASE4CompletedINTERVENTIONAL
Enrollment

2,878

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Overactive BladderUrinary IncontinenceQuality of Life
Interventions
DRUG

oxybutynin transdermal delivery system (Oxytrol(r))

Trial Locations (10)

Unknown

Mobile

Tucson

Torrance

Rocky Hill

Valdosta

Gretna

Bloomfield Hills

Poughkeepsie

Winston-Salem

Tomball

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT00224146 - Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder | Biotech Hunter | Biotech Hunter